ÂÜÀòÂÒÂ×

Mark Capone is a board member at Owlstone Medical. Mark has also served as the interim CEO of Nephrosant, Inc. from February 2021 to May 2022. Prior to that, they were a board observer at Crescendo Bioscience from April 2012 to April 2014. From January 2002 to February 2020, they were a board member at Myriad Genetics.

Mark Capone has a BS in Chemical Engineering from Penn State University and MS degrees in both Chemical Engineering (Biotechnology Emphasis) and Management from the Massachusetts Institute of Technology.